Montana Clinical Trials

A listing of Montana clinical trials actively recruiting patient volunteers.

One of the most rugged and geographically diverse states, Montana's landscape is defined by the Rocky Mountains and Great Plains. Cities include Helena, Billings, Bozeman, and Missoula. Smaller "mountain towns" nestled within the state's alpine ranges drive its skiing industry. Glacier National Park is one of the most popular parks in the United States, offering unparalleled vies of the Rockies. The state is equally famous for its buffalo and deer and for the abundant gold that sparked its settlement. The nonprofit Billings Clinic serves Montana, Wyoming, and the Dakotas, ensuring that even residents in remote areas can access quality care.

Search by Name
Search
Filter by Condition
306 trials found

COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis

NCT04650087

A multicenter, adaptive, randomized platform trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge

Conditions: Covid19

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

NCT04657003

This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).

Conditions: Type 2 Diabetes, Overweight, Obesity

Encorafenib and Binimetinib Plus Pembrolizumab Versus Pembrolizumab for BRAF V600E/K Positive Melanoma

NCT04657991

This is a randomized, double-blind, placebo-controlled, Phase 3 study to compare the efficacy, safety, and tolerability of encorafenib and binimetinib plus pembrolizumab (Triplet Arm) versus placebo plus pembrolizumab (Control Arm) in participants with metastatic or unresectable locally advanced BRAF V600E/K mutation-positive melanoma.

Conditions: Melanoma

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

NCT04660643

This is a study of tirzepatide in participants with obesity or overweight. The main purpose is to learn more about how tirzepatide maintains body weight loss. The study has two phases: a lead-in phase in which all participants take tirzepatide and a treatment phase in which participants will either continue tirzepatide or switch to placebo. The study will last about 2 years (25 visits).

Conditions: Obesity, Overweight

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL

NCT04666038

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT04678206

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Conditions: Refractory Chronic Cough

TTHX1114(NM141) in Combination With DWEK/DSO

NCT04676737

Open label, single-treatment, with a concurrent non-treatment control

Conditions: Fuchs' Endothelial Dystrophy, Fuchs Dystrophy, Fuchs

Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder

NCT04693351

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)

Conditions: Obsessive-Compulsive Disorder

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

NCT04704219

This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.

Conditions: Renal Cell Carcinoma

Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes

NCT04707469

This study compares three doses of once daily semaglutide tablets in people with type 2 diabetes who were previously treated with other oral anti-diabetic medicines. Participants will be initiated on the lowest starting dose of 3 mg and gradually increased until they reach the final trial dose of 14 mg, 25 mg or 50 mg once daily semaglutide tablets. The final three doses will be randomized (i.e., decided by chance). Participants will be administered one tablet per day for 68 weeks. Women cannot ...

Conditions: Diabetes Mellitus, Type 2

Prospective US Radiofrequency SUI Trial

NCT04720352

PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized, sham controlled, double blind study in premenopausal women with stress urinary incontinence. The study will be conducted in 390 subjects, randomized 2:1 with active or sham treatment. Study duration is 12 months post treatment. The primary objective is to evaluate the efficacy of the Viveve treatment, SUI protocol, in improving mild to moderate stress urinary incontinence (SUI), assessed using the 1-hour Pa ...

Conditions: Urinary Incontinence, Stress
Phase: Not Applicable

Early Detection of GEnetic Risk (EDGE)

NCT04746794

The study intervention involves having patients complete a familial cancer risk assessment survey. Those who are found to be at high risk will be offered genetic testing for a panel of hereditary cancers. A "previvor" plan will be created to assist patients and their providers in completing the appropriate follow-up for those with a mutation identified.

Conditions: Genetic Predisposition
Phase: Not Applicable